C
Cameron J. Turtle
Researcher at Fred Hutchinson Cancer Research Center
Publications - 176
Citations - 16390
Cameron J. Turtle is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Chimeric antigen receptor & Immunotherapy. The author has an hindex of 44, co-authored 149 publications receiving 11574 citations. Previous affiliations of Cameron J. Turtle include University of Washington & Seattle Cancer Care Alliance.
Papers
More filters
Journal ArticleDOI
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle,Laïla Aïcha Hanafi,Carolina Berger,Ted Gooley,Sindhu Cherian,Michael Hudecek,Daniel Sommermeyer,Katherine Melville,Barbara S. Pender,Tanya M Budiarto,Emily Robinson,Natalia N Steevens,Colette Chaney,Lorinda Soma,Xueyan Chen,Cecilia Yeung,Brent L. Wood,Daniel Li,Jianhong Cao,Shelly Heimfeld,Michael C. Jensen,Stanley R. Riddell,David G. Maloney +22 more
TL;DR: It is established that high CAR-T cell doses and tumor burden increase the risks of severe cytokine release syndrome and neurotoxicity, and serum biomarkers that allow testing of early intervention strategies in patients at the highest risk of toxicity are identified.
Journal ArticleDOI
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee,Bianca Santomasso,Frederick L. Locke,Armin Ghobadi,Cameron J. Turtle,Jennifer N. Brudno,Marcela V. Maus,Jae H. Park,Elena Mead,Steven Z. Pavletic,William Y. Go,Lamis K. Eldjerou,Rebecca Gardner,Noelle V. Frey,Kevin J. Curran,Karl S. Peggs,Marcelo C. Pasquini,John F. DiPersio,Marcel R.M. van den Brink,Krishna V. Komanduri,Stephan A. Grupp,Sattva S. Neelapu +21 more
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
Journal ArticleDOI
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Harlan Robins,Paulo Vidal Campregher,Santosh Srivastava,Abigail Wacher,Cameron J. Turtle,Cameron J. Turtle,Orsalem J. Kahsai,Stanley R. Riddell,Stanley R. Riddell,Edus H. Warren,Edus H. Warren,Christopher S. Carlson +11 more
TL;DR: A novel experimental and computational approach is developed to measure TCR CDR3 diversity based on single-molecule DNA sequencing, and it is found that total TCRbeta receptor diversity is at least 4-fold higher than previous estimates, and the diversity in the subset of CD45RO(+) antigen-experienced alphabeta T cells is at at least 10-foldHigher than previously estimates.
Journal ArticleDOI
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.
Juliane Gust,Kevin A. Hay,Kevin A. Hay,Laila-Aicha Hanafi,Daniel Li,David Myerson,David Myerson,Luis F. Gonzalez-Cuyar,Cecilia Yeung,Cecilia Yeung,W. Conrad Liles,Mark M. Wurfel,Jose A. Lopez,Junmei Chen,Dominic W. Chung,Susanna Harju-Baker,Tahsin Özpolat,Kathleen R. Fink,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +23 more
TL;DR: Endothelial dysfunction and increased BBB permeability in neurotoxicity are shown and it is found that patients with evidence of endothelial activation before lymphodepletion may be at increased risk of neurotoxicity.
Journal ArticleDOI
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells
Cameron J. Turtle,Cameron J. Turtle,Laila-Aicha Hanafi,Carolina Berger,Carolina Berger,Michael Hudecek,Barbara S. Pender,Emily Robinson,Reed M. Hawkins,Colette Chaney,Sindhu Cherian,Xueyan Chen,Lorinda Soma,Brent L. Wood,Daniel Li,Shelly Heimfeld,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney +19 more
TL;DR: Immunotherapy with CD19 CAR-T cells in a defined CD4+/CD8+ ratio allowed identification of correlative factors for CAR-t cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.